Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
7 Dec 2020
Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Trea...
Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands
7 Dec 2020
Predictive factors for overall survival in chronic myeloid leukaemia patients: a...
Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy
6 Dec 2020
Cranial radiation mostly eliminated in children with T-ALL and bortezomib potent...
Prof David Teachey - The University of Pennsylvania, Rutledge, USA
6 Dec 2020
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukae...
Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA
5 Dec 2020
Evolving concepts in the diagnosis and staging of multiple myeloma
Dr Jens Hillengass - Roswell Park Comprehensive Cancer Center, Buffalo, USA
6 Nov 2020
Recommendations on treating multiple myeloma patients during the pandemic
Dr Jens Hillengass - Roswell Park Comprehensive Cancer Center, Buffalo, USA
6 Nov 2020
Managing multiple myeloma during the COVID-19 pandemic in Brazil
Dr Vania Hungria - Santa Casa de São Paulo, São Paulo, Brazil
3 Nov 2020
Updates in geriatric medical oncology from SIOG meeting
Dr Enrique Soto - Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zu...
28 Oct 2020
OncoAlert and ecancer weekly roundup for October 12 - 18, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
23 Oct 2020
Treating ALL during COVID-19
Prof Mohamad Mohty - Saint-Antoine hospital, Paris, France
20 Oct 2020
Management of infection risk to myeloma patients during the COVID pandemic
Prof Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology, Vienn...
1 Oct 2020
